Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. trimmed its holdings in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 1.2% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,039,987 shares of the company's stock after selling 24,469 shares during the quarter. Assenagon Asset Management S.A. owned 2.37% of Syndax Pharmaceuticals worth $25,061,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Soleus Capital Management L.P. grew its position in Syndax Pharmaceuticals by 128.4% in the 4th quarter. Soleus Capital Management L.P. now owns 2,492,000 shares of the company's stock valued at $32,944,000 after acquiring an additional 1,401,016 shares in the last quarter. Octagon Capital Advisors LP purchased a new stake in Syndax Pharmaceuticals during the fourth quarter worth approximately $11,951,000. Renaissance Technologies LLC purchased a new stake in Syndax Pharmaceuticals during the fourth quarter worth approximately $9,002,000. Trexquant Investment LP lifted its stake in Syndax Pharmaceuticals by 1,309.7% during the fourth quarter. Trexquant Investment LP now owns 471,292 shares of the company's stock worth $6,230,000 after purchasing an additional 437,859 shares during the last quarter. Finally, Altium Capital Management LLC purchased a new stake in Syndax Pharmaceuticals in the fourth quarter valued at approximately $4,891,000.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Wall Street Zen upgraded Syndax Pharmaceuticals to a "sell" rating in a research note on Tuesday, May 6th. Scotiabank upped their target price on Syndax Pharmaceuticals from $16.00 to $17.00 and gave the company a "sector perform" rating in a report on Tuesday, May 6th. JPMorgan Chase & Co. upped their target price on Syndax Pharmaceuticals from $39.00 to $41.00 and gave the company an "overweight" rating in a report on Thursday, March 20th. Guggenheim reaffirmed a "buy" rating and set a $32.00 price objective on shares of Syndax Pharmaceuticals in a research note on Tuesday, May 6th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $51.00 price objective on shares of Syndax Pharmaceuticals in a research note on Tuesday, March 4th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have issued a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $35.91.

Syndax Pharmaceuticals Price Performance

Syndax Pharmaceuticals stock traded down $0.42 during midday trading on Friday, hitting $10.25. 1,310,579 shares of the company were exchanged, compared to its average volume of 1,798,187. The company's fifty day moving average price is $11.24 and its 200-day moving average price is $13.06. The company has a market cap of $881.98 million, a PE ratio of -2.82 and a beta of 0.74. Syndax Pharmaceuticals, Inc. has a fifty-two week low of $8.58 and a fifty-two week high of $25.07.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported ($0.98) EPS for the quarter, topping the consensus estimate of ($1.04) by $0.06. The company had revenue of $20.04 million for the quarter, compared to analyst estimates of $15.88 million. During the same period last year, the firm posted ($0.85) earnings per share. The business's revenue was up 1900.0% on a year-over-year basis. On average, analysts expect that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current fiscal year.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).